GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Purchase Of Investment

Ardelyx (FRA:41X) Purchase Of Investment : €-180.3 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Purchase Of Investment?

Ardelyx's purchase of investment for the three months ended in Mar. 2025 was €-29.2 Mil. It means Ardelyx spent €29.2 Mil on purchasing investments. Ardelyx's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2025 was €-180.3 Mil.

Compared with last quarter (€-94.1 Mil in Dec. 2024 ), Ardelyx spent less money on purchasing investments in Mar. 2025 (€-29.2 Mil).

Ardelyx Purchase Of Investment Historical Data

The historical data trend for Ardelyx's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Purchase Of Investment Chart

Ardelyx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -124.00 -64.37 -47.51 -197.36 -186.38

Ardelyx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.30 -21.22 -35.83 -94.09 -29.18

Ardelyx Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-180.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Ardelyx's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Purchase Of Investment
Comparable Companies
DYN OCUL CLDX LQDA ADPT SPRY IOVA SNDX INVA AUPH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ARDX:USA 41X:Germany
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Website
https://www.ardelyx.com
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines